Insider Selling: BioLife Solutions Inc (BLFS) CEO Sells 12,540 Shares of Stock

BioLife Solutions Inc (NASDAQ:BLFS) CEO Michael Rice sold 12,540 shares of the company’s stock in a transaction that occurred on Tuesday, January 16th. The shares were sold at an average price of $5.57, for a total value of $69,847.80. Following the completion of the sale, the chief executive officer now owns 152,057 shares in the company, valued at $846,957.49. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Shares of BioLife Solutions Inc (NASDAQ:BLFS) traded up $0.03 on Wednesday, reaching $5.63. The company’s stock had a trading volume of 26,145 shares, compared to its average volume of 65,372. BioLife Solutions Inc has a 12-month low of $1.69 and a 12-month high of $7.53. The firm has a market capitalization of $77.15, a price-to-earnings ratio of -13.40 and a beta of 0.27.

BioLife Solutions (NASDAQ:BLFS) last issued its quarterly earnings results on Thursday, November 9th. The medical equipment provider reported ($0.03) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.06) by $0.03. BioLife Solutions had a negative return on equity of 49.92% and a negative net margin of 52.10%. The firm had revenue of $2.96 million for the quarter, compared to analyst estimates of $2.60 million. sell-side analysts anticipate that BioLife Solutions Inc will post -0.21 earnings per share for the current fiscal year.

A number of institutional investors and hedge funds have recently modified their holdings of BLFS. Granite Investment Partners LLC acquired a new position in BioLife Solutions in the third quarter valued at approximately $1,205,000. EAM Investors LLC acquired a new position in BioLife Solutions in the third quarter valued at approximately $555,000. Finally, Essex Investment Management Co. LLC acquired a new position in BioLife Solutions in the third quarter valued at approximately $484,000. 9.15% of the stock is currently owned by hedge funds and other institutional investors.

Separately, Maxim Group upped their target price on BioLife Solutions from $6.00 to $7.00 and gave the company a “buy” rating in a report on Tuesday, September 19th.

COPYRIGHT VIOLATION WARNING: “Insider Selling: BioLife Solutions Inc (BLFS) CEO Sells 12,540 Shares of Stock” was reported by American Banking News and is the property of of American Banking News. If you are accessing this article on another publication, it was copied illegally and republished in violation of US and international copyright and trademark legislation. The legal version of this article can be viewed at https://www.americanbankingnews.com/2018/01/17/insider-selling-biolife-solutions-inc-blfs-ceo-sells-12540-shares-of-stock.html.

BioLife Solutions Company Profile

BioLife Solutions, Inc (BioLife) is engaged in the developing, manufacturing and marketing a portfolio of biopreservation tools and services for cells, tissues and organs, including clinical grade cell and tissue hypothermic storage and cryopreservation freeze media and a related cloud hosted biologistics cold chain management application for shippers.

Receive News & Ratings for BioLife Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLife Solutions and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply